The Hordaland Health Study

The Hordaland Health Studies (HHS) were conducted in 1992-93 (The Homocysteine study) and in 1997-99 (HUSK). Both surveys were conducted as a joint project between the University of Bergen, the Norwegian Health Screening Service (SHUS) (now part of the National Institute of Public Health) and the Municipal Health Service in Hordaland.

The main focus of the studies is on chronic diseases including cardiovascular disease, cancer, osteoporosis, anxiety and depression. Some projects focus on psychosocial factors, occupational research, musculoskeletal diseases, urinary incontinence and mapping of drug use. The main purpose of the surveys is to gather information so that disease ultimately can be prevented.

Approximately 36,000 residents of Hordaland county participated in the studies, ca. 18,000 in 1992-93 and ca. 26,000 in 1997-99. About 7,000 of those who participated in the 1992-93 survey also participated in 1997-99.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Disease Disease Attributes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

40 year–74 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Born in a specific time-period
From Hordaland County
Community-dwelling people who were able to come to the study site on their own, and able to fill out questionnaires.

Exclusion criteria

Not born within the specific time-period
Not from Hordaland County
Institutionalized People
People who were not able to fill out questionnaires

Treatment and study plan

No intervention

Other

No intervention

Primary outcomes

Total mortality.

Time frame: Participants are followed from baseline (1992-93 or 1997-99) until death or December 31st, 2015.

The unique 11-digit personal identification number assigned to all Norwegian residents facilitates linkage between HHS and the Norwegian Population Register, which contains information on vital status (alive, emigrated, or dead). The follow-up period varies from 16 - 23 years, depending on whether first or second measurement is used as baseline.

Secondary outcomes

Mortality or morbidity from chronic diseases (for example cardiovascular disease, cancer). Also, award of disability pension are used as an outcome.

Time frame: Participants are followed from baseline (1992-93 or 1997-99) until time of diagnosis/death from disease or the last day of follow-up.

The Cause of Death Registry, Cancer Registry of Norway, CVDNOR and FD-trygd (a national database of Health and social benefits) will be used to get information on outcomes. The last day of follow-up for cardiovascular disease is December 31st, 2014. The last day of follow-up for cancer is December 31st, 2014.

The last day of follow-up for Cause of Death is December 31st, 2014. The follow-up period for cardiovascular disease varies from 15 - 22 years, depending on whether first or second measurement is used as baseline.

The follow-up period for cancer varies from 15 - 22 years, depending on whether first or second measurement is used as baseline.

Sponsors and collaborators

Lead sponsor

University of Bergen

Other

Collaborators

Part of CONOR, and participates in the Norwegian Epidemiologic Osteoporosis Studies

Registry information

Official study title

The Hordaland Health Studies (HHS)

Acronym: HUSK

Important dates

Study start: 1992
Primary completion: 1999
Study completion: 1999
First posted: Jan 6, 2017
Registry last updated: Jan 6, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed